Teerlink JR - Search Results

1

Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.

Psotka MA, Teerlink JR. Psotka MA, et al. Among authors: teerlink jr. Handb Exp Pharmacol. 2017;243:465-490. doi: 10.1007/164_2017_13. Handb Exp Pharmacol. 2017. PMID: 28315072 Review.

2

The role of endothelin in the pathogenesis of heart failure.

Teerlink JR. Teerlink JR. Curr Cardiol Rep. 2002 May;4(3):206-12. doi: 10.1007/s11886-002-0052-2. Curr Cardiol Rep. 2002. PMID: 11960589

3

The development of new medical treatments for acute decompensated heart failure.

Teerlink JR. Teerlink JR. Heart Fail Monit. 2002;2(4):129-37. Heart Fail Monit. 2002. PMID: 12634887 Review.

4

Overview of randomized clinical trials in acute heart failure syndromes.

Teerlink JR. Teerlink JR. Am J Cardiol. 2005 Sep 19;96(6A):59G-67G. doi: 10.1016/j.amjcard.2005.07.022. Am J Cardiol. 2005. PMID: 16181824 Review.

5

COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.

Greenberg BH, Mehra M, Teerlink JR, Ordronneau P, McCollum D, Gilbert EM. Greenberg BH, et al. Among authors: teerlink jr. Am J Cardiol. 2006 Oct 2;98(7A):53L-59L. doi: 10.1016/j.amjcard.2006.08.003. Epub 2006 Aug 28. Am J Cardiol. 2006. PMID: 17023233

6

Irbesartan in patients with heart failure and preserved ejection fraction.

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Massie BM, et al. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11. N Engl J Med. 2008. PMID: 19001508 Free article. Clinical Trial.

7

A novel approach to improve cardiac performance: cardiac myosin activators.

Teerlink JR. Teerlink JR. Heart Fail Rev. 2009 Dec;14(4):289-98. doi: 10.1007/s10741-009-9135-0. Heart Fail Rev. 2009. PMID: 19234787 Free PMC article. Review.

8

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.

Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD. Teerlink JR, et al. Heart Fail Rev. 2009 Dec;14(4):243-53. doi: 10.1007/s10741-009-9153-y. Heart Fail Rev. 2009. PMID: 19876734 Free PMC article. Review.

9

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Teerlink JR, et al. Lancet. 2011 Aug 20;378(9792):667-75. doi: 10.1016/S0140-6736(11)61219-1. Lancet. 2011. PMID: 21856480 Clinical Trial.

10

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. Cleland JG, et al. Among authors: teerlink jr. Lancet. 2011 Aug 20;378(9792):676-83. doi: 10.1016/S0140-6736(11)61126-4. Lancet. 2011. PMID: 21856481 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

361 results

Search Page

Filters